Mersana Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch MRSN and buy or sell other stocks, ETFs, and their options commission-free!About MRSN
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592.
CEOMartin H. Huber
CEOMartin H. Huber
Employees102
Employees102
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2001
Founded2001
Employees102
Employees102
MRSN Key Statistics
Market cap4.07B
Market cap4.07B
Price-Earnings ratio-12.83
Price-Earnings ratio-12.83
Dividend yield—
Dividend yield—
Average volume2.98M
Average volume2.98M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$2.83
52 Week high$2.83
52 Week low$0.2589
52 Week low$0.2589
Stock Snapshot
As of today, Mersana Therapeutics(MRSN) shares are valued at $29.08. The company's market cap stands at 4.07B, with a P/E ratio of -12.83.
On 2026-01-07, Mersana Therapeutics(MRSN) stock opened at —, reached a high of —, and a low of —.
Mersana Therapeutics(MRSN) shares are trading with a volume of 0, against a daily average of 2.98M.
In the last year, Mersana Therapeutics(MRSN) shares hit a 52-week high of $2.83 and a 52-week low of $0.26.
In the last year, Mersana Therapeutics(MRSN) shares hit a 52-week high of $2.83 and a 52-week low of $0.26.
People also own
Based on the portfolios of people who own MRSN. This list is generated using Robinhood data, and it’s not a recommendation.